The frontier of drug delivery has moved beyond the cell membrane to target specific organelles. While previous breakthroughs, such as DNA origami nanopores, focused on breaching the cellular barrier to monitor or treat neurons, a new milestone has been reached in subcellular precision: the FDA approval of elamipretide.

Add AlexTech.ai asPreferred Source on Google

Approved in September 2025 for the treatment of Barth syndrome, elamipretide (marketed as Forzinity) represents the culmination of a twenty-year research journey led by pharmacologist Hazel Szeto at Weill Cornell Medicine. The drug is designed to improve muscle strength in adults and children weighing at least 30kg suffering from this rare genetic condition.

The mechanism of mitochondrial targeting

The discovery began in 2004 when Szeto identified a small peptide secreted by frogs that acted as an analgesic. However, the most significant characteristic of this molecule was its ability to penetrate cells and accumulate specifically within the mitochondria—the organelles responsible for chemical energy production.

Unlike many complex drug delivery systems, these aromatic-cationic peptides (known as Szeto-Schiller peptides) are water-soluble and can penetrate cells without the need for elaborate delivery mechanisms. Once inside, they target cardiolipin in the inner mitochondrial membrane to protect against oxidative stress and promote electron transfer.

Beyond Barth syndrome

The approval of elamipretide opens the door to a broader field of mitochondrial medicine. Because mitochondrial dysfunction is linked to various pathologies, this subcellular targeting approach could potentially be applied to:

  • Cardiovascular health: Minimizing tissue damage after heart attacks or strokes.
  • Neurodegenerative diseases: Treating conditions such as Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS).
  • Metabolic disorders: Addressing insulin resistance and diabetic complications.

By focusing on the inner membrane where the electron transport chain resides, these compounds aim to reduce free radical production and prevent cell death by apoptosis or necrosis, addressing the underlying cause of many aging-related diseases.